View as cardsView as table106 Projects

Development of a synthetic promoter pipeline for safe and efficient gene therapy

Fiscal Year Awarded:

2024

Principal Investigator:

George Church

Development of novel AAV-mediated in vivo gene editing approaches to treat inherited collagen VI-related myopathies

Fiscal Year Awarded:

2024

Principal Investigator:

Amy Wagers

Functional antibody screening with micro-capsules - proof of concept with anti-EGFR

Fiscal Year Awarded:

2024

Principal Investigator:

Allon Klein

Gene editing to treat hereditary deafness

Fiscal Year Awarded:

2024

Principal Investigator:

David Corey

Identification of small molecule binders of the novel cancer immunotherapy target Bird33

Fiscal Year Awarded:

2024

Principal Investigator:

Arlene Sharpe

Multimodal imaging and machine learning for diagnosis and patient stratification with predictive biomarkers

Fiscal Year Awarded:

2024

Principal Investigator:

Peter Sorger

Small molecule therapeutics for HPV associated cancers

Fiscal Year Awarded:

2024

Principal Investigator:

Peter Howley

Structure-based discovery and optimization of novel angiotensin receptor modulators

Fiscal Year Awarded:

2024

Principal Investigator:

Andrew Kruse

Targeting tumor endothelial cells for cancer immunotherapy with cytokines

Fiscal Year Awarded:

2024

Principal Investigator:

Ulrich von Andrian

Using microbiome-derived small molecules to augment cancer immunotherapy

Fiscal Year Awarded:

2024

Principal Investigator:

Marco Jost

A kinase inhibitor for malignant brain tumors

Fiscal Year Awarded:

2023

Principal Investigator:

Timothy Mitchison

Agents modulating B cell activation through the CD81-CD19 co-receptor complex

Fiscal Year Awarded:

2023

Principal Investigator:

Stephen Blacklow

Antibody-based therapeutics against Nipah virus

Fiscal Year Awarded:

2023

Principal Investigator:

Jonathan Abraham

Brain-penetrant kinase inhibitors targeting Alzheimer's and related dementias

Fiscal Year Awarded:

2023

Principal Investigator:

Mark Albers

Evaluating antisense oligos for therapeutic impact in liver fibrosis and hepatocellular carcinoma

Fiscal Year Awarded:

2023

Principal Investigator:

Karen Adelman

Identification of druggable targets against Vibrio pathogens

Fiscal Year Awarded:

2023

Principal Investigator:

Norbert Perrimon

Manipulating mitobiogenesis by targeting ME2

Fiscal Year Awarded:

2023

Principal Investigator:

David Scadden

Methods and applications of semi-permeable capsules with current application to high-throughput single cell multi-omics

Fiscal Year Awarded:

2023

Principal Investigator:

Allon Klein

A natural beta interferon-inducing therapeutic glycolipid from the microbiome that prevents and treats severe viral infection

Fiscal Year Awarded:

2022

Principal Investigator:

Dennis Kasper

A platform for transcriptome time-series in single cells with applications to hematopoietic stem cells

Fiscal Year Awarded:

2022

Principal Investigator:

Johan Paulsson